ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Task Force Reorganized, Foiled By Snow

March 2, 1979

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

December 30, 2011

NCI Relates FDA Instructions On Latest IND Delays

October 29, 1976

NCI Posts Website Usability Research, Information Online.

January 12, 2001

In Brief: Former Oklahoma Re. Synar, Opponent of Tobacco, dead at 45 Of Brain Cancer

January 12, 1996

In Brief: Bishop No Longer Candidate For NCI Director; HHS Endorses Intramural Scientist Klausner

April 21, 1995